New diabetes pill XW014 enters first human safety tests
NCT ID NCT05579314
First seen Oct 31, 2025 · Last updated May 11, 2026 · Updated 26 times
Summary
This early-stage study tested an experimental oral drug called XW014 in 127 healthy volunteers and people with type 2 diabetes. The main goal was to check safety and how the body processes the drug, including the effect of food. Researchers gave single or multiple doses to find the right dose range for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON - Early Development Services
Lenexa, Kansas, 66219, United States
-
ICON - Early Development Services
San Antonio, Texas, 78209, United States
-
ICON - Early Development Services
Salt Lake City, Utah, 84124, United States
Conditions
Explore the condition pages connected to this study.